The Gale Encyclopedia of Neurological Disorders Vol 2 (M Z) pdf

  The GALE

  

ENCYCLOPEDIA of

N

  Eurological D isorders

  

VOLUME

M - Z

G L O S S A R Y

  

I N D E X

  GALE

ENCYCLOPEDIA of

  N Eurological

  

D isorders

S T A C E Y L . C H A M B E R L I N , B R I G H A M N A R I N S , E D I T O R S

  Project Editors Stacey L. Chamberlin, Brigham Narins Editorial Erin Watts Editorial Support Services Andrea Lopeman Indexing Services Synapse

  

For permission to use material from this

product, submit your request via the web at

http://www.gale-edit.com/permission or you

may download our Permissions Request form

and submit your request by fax or mail to: Permissions Thomson Gale 27500 Drake Rd. Farmington Hills, MI 48331-3535 Permissions Hotline: 248-699-8006 or 800-877-4253, ext. 8006 Fax: 248-699-8074 or 800-762-4058

  ISBN 0-7876-9150-X (set hardcover : alk. paper) — ISBN 0-7876-9151-8 (v. 1) — ISBN 0-7876-9152-6 (v. 2) 1. Neurology—Encyclopedias.

  

The Gale encyclopedia of neurological disorders / Stacey L. Chamberlin, Brigham Narins,

editors. p. ; cm. Includes bibliographical references and index.

  

ISBN 0-7876-9160-7 (set)

Contact your Gale sales representative for ordering information.

Printed in the United States of America

  

The Gale Encyclopedia of Neurological Disorders

This title is also available as an e-book.

  While every effort has been made to ensure the reliability of the information presented in this publication, Thomson Gale does not guarantee the accuracy of the data contained herein. Thomson Gale accepts no payment for listing; and inclusion in the publication of any organization, agency, institution, publication, service, or individual does not imply endorsement of the editors or publisher. Errors brought to the attention of the publisher and verified to the satisfaction of the publisher will be corrected in future editions.

  Since this page cannot legibly accommodate all copyright notices, the acknowledgments constitute an extension of the copyright notice.

  This publication is a creative work fully

protected by all applicable copyright laws, as

well as by misappropriation, trade secret,

unfair condition, and other applicable laws.

The authors and editors of this work have added value to the underlying factual

material herein through one or more of the

following: coordination, expression, arrangement, and classification of the information.

  Rights Acquisitions Management

Margaret Chamberlain, Jackie Jones, Shalice

Shah-Caldwell Imaging and Multimedia

Randy Basset, Lezlie Light, Dan Newell, Robyn

  No part of this work covered by the copyright hereon may be reproduced or used in any form or by any means—graphic, electronic, or mechanical, including photocopying, record- ing, taping, Web distribution, or information storage retrieval systems—without the writ- ten permission of the publisher.

  27500 Drake Rd. Farmington Hills, MI 48331-3535 Or you can visit our Internet site at http://www.gale.com

  For more information, contact The Gale Group, Inc.

  Corporation. Thomson and Star Logo are trademarks and Gale is a registered trademark used herein under license.

  Composition and Electronic Prepress Evi Seoud, Mary Beth Trimper Manufacturing Wendy Blurton, Dorothy Maki ©2005 Thomson Gale, a part of The Thomson

  Product Design Michelle DiMercurio, Tracey Rowens, Kate Scheible

  [DNLM: 1. Nervous System Diseases—Encyclopedias—English. 2. Nervous System Diseases—Popular Works. WL 13 G151 2005] I. Title: Encyclopedia of neurological

disorders. II. Chamberlin, Stacey L. III. Narins, Brigham, 1962– IV. Gale Group.

RC334.G34 2005

616.8'003—dc22 2004021644

  

CONTENTS

List of Entries ................................................vii

Introduction ..................................................xiii

Advisory Board..............................................xv

Contributors .................................................xvii

Entries Volume 1: A–L ........................................................1 Volume 2: M–Z ...................................................511

Glossary .......................................................941

General Index...............................................973

A

B

  ❙

  Congenital myasthenia Congenital myopathies Corpus callosotomy Corticobasal degeneration Craniosynostosis Craniotomy Creutzfeldt-Jakob disease CT scan Cushing syndrome Cytomegalic inclusion body disease

  ❙

  Back pain Bassen-Kornzweig syndrome Batten disease Behçet disease Bell’s palsy Benign positional vertigo Benzodiazepines Beriberi Binswanger disease Biopsy Blepharospasm Bodywork therapies Botulinum toxin Botulism Brachial plexus injuries Brain anatomy Brain and spinal tumors Brown-Séquard syndrome

  Abulia Acetazolamide Acupuncture Acute disseminated encephalomyelitis Adrenoleukodystrophy Affective disorders Agenesis of the corpus callosum Agnosia AIDS Alcohol-related neurological disease Alexander disease Alpers’ disease Alternating hemiplegia Alzheimer disease Amantadine Amnestic disorders Amyotrophic lateral sclerosis Anatomical nomenclature Anencephaly Aneurysms Angelman syndrome Angiography Anosmia Anticholinergics Anticonvulsants Antiepileptic drugs Antimigraine medications Antiparkinson drugs Antiviral drugs Anxiolytics Aphasia Apraxia Arachnoid cysts Arachnoiditis Arnold-Chiari malformation Arteriovenous malformations Aspartame Asperger’s disorder Assistive mobile devices Ataxia-telangiectasia Ataxia Atomoxetine Attention deficit hyperactivity disorder Autism Autonomic dysfunction

D

C

  Central nervous system Central nervous system stimulants Central pain syndrome Cerebellum Cerebral angiitis Cerebral cavernous malformation Cerebral circulation Cerebral dominance Cerebral hematoma Cerebral palsy Channelopathies Charcot-Marie-Tooth disorder Cholinergic stimulants Cholinesterase inhibitors Chorea Chronic inflammatory demyelinating polyneuropathy Clinical trials

  Dandy-Walker syndrome Deep brain stimulation Delirium Dementia Depression Dermatomyositis Devic syndrome Diabetic neuropathy disease Diadochokinetic rate Diazepam Dichloralphenazone Dichloralphenazone, Isometheptene, and Acetaminophen Diencephalon

  Diet and nutrition Disc herniation Dizziness Dopamine receptor agonists Dysarthria Dysesthesias Dysgeusia Dyskinesia Dyslexia Dyspraxia Dystonia Electroencephalography Electromyography Empty sella syndrome Encephalitis and Meningitis Encephalitis lethargica Encephaloceles Encephalopathy Endovascular embolization Epidural hematoma Epilepsy Exercise

  ❙ E

  Electric personal assistive mobility devices

  Canavan disease Carbamazepine Carotid endarterectomy Carotid stenosis Carpal tunnel syndrome Catechol-O-methyltransferase inhibitors Central cord syndrome

  ❙

  ❙

J

N

  ❙

  Machado-Joseph disease

Magnetic resonance imaging (MRI)

Megalencephaly Melodic intonation therapy Ménière’s disease Meninges Mental retardation Meralgia paresthetica Metachromatic leukodystrophy Microcephaly Mitochondrial myopathies Modafinil Moebius syndrome Monomelic amyotrophy Motor neuron diseases Movement disorders Moyamoya disease Mucopolysaccharidoses Multi-infarct dementia Multifocal motor neuropathy

  List of Entries

  Pain Pallidotomy Pantothenate kinase-associated neurodegeneration Paramyotonia congenita Paraneoplastic syndromes Parkinson’s disease Paroxysmal hemicrania Parsonage-Turner syndrome Perineural cysts Periodic paralysis Peripheral nervous system Peripheral neuropathy Periventricular leukomalacia Phantom limb Pharmacotherapy Phenobarbital Pick disease Pinched nerve Piriformis syndrome Plexopathies Poliomyelitis

  ❙

  Occipital neuralgia Olivopontocerebellar atrophy Opsoclonus myoclonus Organic voice tremor Orthostatic hypotension Oxazolindinediones

  ❙

  Narcolepsy Nerve compression Nerve conduction study Neurofibromatosis Neuroleptic malignant syndrome Neurologist Neuromuscular blockers Neuronal migration disorders Neuropathologist Neuropsychological testing Neuropsychologist Neurosarcoidosis Neurotransmitters Niemann-Pick Disease

  Fabry disease Facial synkinesis Fainting Fatigue Febrile seizures Felbamate Fisher syndrome Foot drop Fourth nerve palsy Friedreich ataxia

  Multiple sclerosis Multiple system atrophy Muscular dystrophy Myasthenia, congenital Myasthenia gravis Myoclonus Myofibrillar myopathy Myopathy Myotonic dystrophy

  ❙

F

  Gabapentin Gaucher disease Gene therapy Gerstmann-Straussler-Scheinker disease Gerstmann syndrome Glossopharyngeal neuralgia Glucocorticoids Guillain-Barré syndrome

  ❙

  Kennedy’s disease Klippel Feil syndrome Krabbe disease Kuru

  Joubert syndrome ❙

  ❙

K

L

G

  ❙

  

Lambert-Eaton myasthenic syndrome

Laminectomy Lamotrigine Learning disorders Lee Silverman voice treatment Leigh disease Lennox-Gastaut syndrome Lesch-Nyhan syndrome Leukodystrophy Levetiracetam Lewy body dementia Lidocaine patch Lissencephaly Locked-in syndrome Lupus Lyme disease

O

P

H

  ❙

  Hallucination Headache Hearing disorders Hemianopsia Hemifacial spasm Hereditary spastic paraplegia Holoprosencephaly HTLV-1 Associated Myelopathy Huntington disease Hydantoins Hydranencephaly Hydrocephalus Hydromyelia Hypersomnia Hypotonia Hypoxia

M

  ❙

  I Idiopathic neuropathy Inclusion body myositis Incontinentia pigmenti Infantile spasms Inflammatory myopathy Interferons Polymyositis Pompe disease Porencephaly Positron emission tomography (PET) Post-polio Syndrome Primary lateral sclerosis Primidone Prion diseases Progressive multifocal leukoencephalopathy Progressive supranuclear palsy Pseudobulbar palsy Pseudotumor cerebri

  ❙

U

V Valproic acid and divalproex

R

  ❙

  Radiation Radiculopathy Ramsay-Hunt syndrome type II Rasmussen’s encephalitis Reflex sympathetic dystrophy Refsum disease Repetitive motion disorders Respite Restless legs syndrome Rett syndrome Reye syndrome

T

W

  Zellweger syndrome Zonisamide List of Entries

  ❙

  Wallenberg syndrome West Nile virus infection Whiplash Whipple’s Disease Williams syndrome Wilson disease

  ❙

  sodium Vasculitic neuropathy Vasculitis Ventilatory assistance devices Ventricular shunt Ventricular system Vertebrobasilar disease Vestibular schwannoma Visual disturbances Vitamin/nutritional deficiency Von Hippel-Lindau disease

  Ulnar neuropathy Ultrasonography ❙

  ❙

  Tremors Trigeminal neuralgia Tropical spastic paraparesis Tuberous sclerosis

  Tabes dorsalis Tay-Sachs disease Temporal arteritis Temporal lobe epilepsy Tethered spinal cord syndrome Third nerve palsy Thoracic outlet syndrome Thyrotoxic myopathy Tiagabine Todd’s paralysis Topiramate Tourette syndrome Transient global amnesia Transient ischemic attack Transverse myelitis Traumatic brain injury

  ❙

  Sixth nerve palsy Sjogren-Larsson Syndrome Sleep apnea Social workers Sodium oxybate Sotos syndrome Spasticity Speech synthesizer Spina bifida Spinal cord infarction Spinal cord injury Spinal muscular atrophy Spinocerebellar ataxia Status epilepticus Stiff person syndrome Striatonigral degeneration Stroke Sturge-Weber syndrome Stuttering Subacute sclerosing panencephalitis Subdural hematoma Succinamides Swallowing disorders Sydenham’s chorea Syringomyelia

S

  Sandhoff disease Schilder’s disease Schizencephaly Schizophrenia Sciatic neuropathy Sciatica Seizures Septo-optic dysplasia Shaken baby syndrome Shingles Single Proton Emission Computed Tomography

  ❙

Z

  

PLEASE READ—IMPORTANT INFORMATION

The Gale Encyclopedia of Neurological Disorders is

  a medical reference product designed to inform and edu- cate readers about a wide variety of diseases, syndromes, drugs, treatments, therapies, and diagnostic equipment. Thomson Gale believes the product to be comprehensive, but not necessarily definitive. It is intended to supplement, not replace, consultation with a physician or other health- care practitioner. While Thomson Gale has made sub- stantial efforts to provide information that is accurate, comprehensive, and up-to-date, Thomson Gale makes no representations or warranties of any kind, including with- out limitation, warranties of merchantability or fitness for a particular purpose, nor does it guarantee the accuracy, comprehensiveness, or timeliness of the information con- tained in this product. Readers are advised to seek profes- sional diagnosis and treatment for any medical condition, and to discuss information obtained from this book with their healthcare providers.

  

INTRODUCTION

The Gale Encyclopedia of Neurological Disorders

  (GEND) is a one-stop source for medical information that covers diseases, syndromes, drugs, treatments, therapies, and diagnostic equipment. It keeps medical jargon to a minimum, making it easier for the layperson to use. The

  Gale Encyclopedia of Neurological Disorders presents au-

  thoritative and balanced information and is more compre- hensive than single-volume family medical guides.

Treatments

  • Definition • Purpose • Precautions • Description • Preparation • Aftercare • Risks • Normal results
  • Resources • Key terms

  SCOPE

  Almost 400 full-length articles are included in The

  Gale Encyclopedia of Neurological Disorders. Articles

  follow a standardized format that provides information at a glance. Rubrics include:

Diseases

  • Definition • Description • Demographics • Causes and symptoms
  • Diagnosis • Treatment team
  • Treatment • Recovery and rehabilitation
  • Clinical trials
  • Prognosis • Special concerns
  • Resources • Key terms

  A preliminary topic list was compiled from a wide va- riety of sources, including professional medical guides, consumer guides, and textbooks and encyclopedias. The advisory board, made up of seven medical and healthcare experts, evaluated the topics and made suggestions for in- clusion. Final selection of topics to include was made by the medical advisors in conjunction with Gale editors.

Drugs

  The essays were compiled by experienced medical writers, physicians, nurses, and pharmacists. GEND med- ical advisors reviewed most of the completed essays to in- sure that they are appropriate, up-to-date, and medically accurate.

  • Definition • Purpose • Description • Recommended dosage
  • Precautions • Side effects
  • Interactions • Resources • Key terms

  HOW TO USE THIS BOOK reference for the rare childhood disease commonly known

  as Hallervorden-Spatz disease that points to the entry en- The Gale Encyclopedia of Neurological Disorders titled Pantothenate kinase-associated neurodegeneration. has been designed with ready reference in mind:

  oduction

  • A Resources section directs users to sources of further
  • Straight

  alphabetical arrangement allows users to lo-

Intr

  information, which include books, periodicals, websites, cate information quickly. and organizations.

  • Bold faced terms function as print hyperlinks that point
  • A glossary is included to help readers understand unfa- the reader to full-length entries in the encyclopedia.

  miliar terms.

  • A list of

  key terms is provided where appropriate to de-

  • A comprehensive general index allows users to easily fine unfamiliar words or concepts used within the con- target detailed aspects of any topic.

  text of the essay.

  Cross-references placed throughout the encyclopedia di- • GRAPHICS

  rect readers to where information on subjects without their own entries can be found. Cross-references are also used to The Gale Encyclopedia of Neurological Disorders is assist readers looking for information on diseases that are enhanced with over 100 images, including photos, tables, now known by other names; for example, there is a cross- and customized line drawings.

  

An advisory board made up of prominent individuals from the medical and healthcare communities provided invaluable assis-

tance in the formulation of this encyclopedia. They defined the scope of coverage and reviewed individual entries for accu-

racy and accessibility; in some cases they contributed entries themselves. We would therefore like to express our great

appreciation to them: Laurie Barclay, MD Brenda Wilmoth Lerner, RN Roy Sucholeiki, MD Neurologist and Writer Nurse, Writer, and Editor Professor, Director of the

  Tampa, FL London, UK Comprehensive Epilepsy

  Program

  Department of Neurology

  Pharmacist, Clinician, Writer, Associate Professor

  Loyola University Health System

  Editor, and Consultant Clinical Neurosciences

  Chicago, IL Swansea, IL Stanford University School of

  Medicine Gil I. Wolfe, MD

  Joel C. Kahane, PhD

  Stanford, CA Associate Professor

  Professor, Director of the

  Department of Neurology

Anatomical Sciences Laboratory

  The University of Texas The School of Audiology and

  Southwestern Medical Center Speech-Language Pathology

  Dallas, TX The University of Memphis Memphis, TN

  

CONTRIBUTORS

Lisa Maria Andres, MS, CGC Certified Genetic Counselor and Medical Writer

  Robert G. Best, PhD Director

  James Paul Dworkin, PhD

Professor

  Bruno Verbeno Azevedo

  Department of Embryology, Obstetrics, and Gynecology

  Adam J. Cohen, MD Craniofacial Surgery, Eyelid and Facial Plastic Surgery,

  Neuro-Ophthalmology

  Downers Grove, IL

  Tish Davidson, AM Medical Writer

  Fremont, CA

  Paul Arthur Science writer

  Department of Otolaryngology, Voice/Speech Pathology Program and Laboratory

  Wayne State University Detroit, MI

  L. Fleming Fallon, Jr., MD, DrPH Professor

  Department of Public Health Bowling Green State University Bowling Green, OH

  Antonio Farina, MD, PhD

  University of Bologna Bologna, Italy

  Institute for Molecular and Human Genetics

  Kevin Fitzgerald Science Writer and Journalist

  South Windsor, CT

  Paula Anne Ford-Martin Medical Writer

  Warwick, RI

  Lisa A. Fratt Medical Writer

  Ashland, WI

  Rebecca J. Frey, PhD Freelance Medical Writer

  New Haven, CT

  Sandra L. Friedrich, MA Science Writer

  Clinical Psychology Chicago, IL

  Sandra Galeotti, MS Science Writer

  Sao Paulo, Brazil

  Georgetown University Washington, D.C.

  Bryan Richard Cobb, PhD

  Espirito Santo University Vitória, Brazil

  TCB Research Boalsburg, PA

  Deepti Babu, MS, CGC Genetic Counselor

  Marshfield Clinic Marshfield, WI

  Laurie Barclay, MD Neurologist and writer

  Tampa, FL

  Julia Barrett Science Writer

  Madison, WI

  Danielle Barry, MS Graduate Assisstant

  Center of Alcohol Studies Rutgers University Piscataway, NJ

  Maria Basile, PhD Medical Writer

  Roselle, NJ

  Tanja Bekhuis, PhD Science Writer and Psychologist

  Juli M. Berwald, PhD Geologist (Ocean Sciences)

  Fairfax, VA

  Chicago, Illinois

  London, England

  Division of Genetics University of South Carolina School of Medicine Columbia, SC

  Michelle Lee Brandt Medical Writer

  San Francisco, CA

  Dawn J. Cardeiro, MS, CGC Genetic Counselor

  Fairfield, PA

  Francisco de Paula Careta

  Espirito Santo University Vitória, Brazil

  Rosalyn Carson-DeWitt, MD Physician and Medical Writer

  Durham, NC

  San Jose, CA

  Stacey L. Chamberlin Science Writer and Editor

  Larry Gilman, PhD Electrical Engineer and Science Writer

  Nicole Mallory, MS, PA-C Medical Student

  Alfredo Mori, MD, FACEM, FFAEM

  Warren, MI

  Michael Mooney, MA, CAC Consultant Psychotherapist

  School of Medicine University of Rijeka Pula, Croatia

  Igor Medica, MD, PhD Assistant Professor

  Wayne State University Detroit, MI

Emergency Physician

  Iuri Drumond Louro, MD, PhD Adjunct Professor

  Human and Molecular Genetics Espirito Santo University Vitória, Brazil

  Based Health Care University of Oxford Oxford, England

  Foster City, CA

  University of California, San Francisco

  Department of Biomagnetic Imaging

  Member: American Academy of Neurology, American Association of Electrodiagnostic Medicine

  Peter T. Lin, MD

  University of Queensland Brisbane, Australia

  The Alfred Hospital Victoria, Australia Oxford’s Program in Evidence-

  Marcos do Carmo Oyama

  

Agnieszka Maria Lichanska,

PhD

  J. Ricker Polsdorfer, MD Medical Writer

  Contributors

  Clinipharm Services Seal Beach, CA

  Jack Raber, PharmD Principal

  Buffalo Grove, IL

  Scott J. Polzin, MS, CGC Medical Writer

  Phoenix, AZ

  Baltimore, MD

  Espirito Santo University Vitória, Brazil

  University of Maryland School of Medicine

  Division of Endocrinology, Diabetes, and Nutrition

  Toni I. Pollin, MS, CGC

  Division of Medical Genetics University Medical Center Lubiana, Slovenia

  Borut Peterlin, MD, PhD Neurologist; Consultant Clinical Geneticist; Director

  Espirito Santo University Vitória, Brazil

  Greiciane Gaburro Paneto

  Department of Microbiology and Parasitology

  Science Policy Institute London, UK

  Sharon, VT

  Stephen John Hage, AAAS, RT(R), FAHRA Medical Writer

  Montreal, Canada

  Brian Douglas Hoyle, PhD Microbiologist

  Nova Scotia, Canada

  Cindy L. Hunter, CGC Genetic Counselor

  Medical Genetics Department Indiana University School of

  Medicine Indianapolis, IN

  Alexander I. Ioffe, PhD Senior Scientist

  Dan Harvey Medical Writer

  K. Lee Lerner Fellow (rt)

  Loomis, CA

  Brook Ellen Hall, PhD Science Writer

  Chatsworth, CA

  Lathrup Village, MI

  Wilmington, DE

  Laith Farid Gulli, MD Consulting Psychotherapist

  Kelly Karpa, PhD, RPh Assistant Professor

  Department of Pharmacology Pennsylvania State University

  College of Medicine Hershey, PA

  

Karen M. Krajewski, MS, CGC

Genetic Counselor, Assistant Professor of Neurology

  Wayne State University Detroit, MI

  Judy Leaver, MA

Behavioral Health Writer and

Consultant

  Washington, D.C.

  Adrienne Wilmoth Lerner

  University of Tennessee College of Law

  Knoxville, TN

  

Brenda Wilmoth Lerner, RN

Nurse, Writer, and Editor

  London, UK

  Hannah M. Hoag, MSc Science and Medical Writer

Research Analyst

  Geological Institute of the Russian Academy of Sciences

Research Assistant

  Holly Ann Ishmael, MS, CGC Genetic Counselor

  The Children’s Mercy Hospital Kansas City, MO

  Joel C. Kahane, PhD Professor, Director of the Anatomical Sciences

  Laboratory

  The School of Audiology and Speech-Language Pathology

  The University of Memphis Memphis, TN

  Moscow, Russia

  Robert Ramirez, DO Medical Student

  Lancaster, PA

  Department of Neurology Loyola University Health System Chicago, IL

  Kevin M. Sweet, MS, CGC Cancer Genetic Counselor

  James Cancer Hospital, Ohio State University

  Columbus, OH

  David Tulloch Science Writer

  Wellington, New Zealand

  Carol A. Turkington Medical Writer

  Samuel D. Uretsky, PharmD Medical Writer

  Roy Sucholeiki, MD Professor, Director of the Comprehensive Epilepsy

  Wantagh, NY

  Chitra Venkatasubramanian, MBBS, MD (internal medicine) Resident in Neurology

  Department of Neurology and Neurosciences

  Stanford University Stanford, CA.

  Bruno Marcos Verbeno

  Espirito Santo University Vitória, Brazil

  Beatriz Alves Vianna

  Espirito Santo University Vitória, Brazil

  Program

  Greenwood Genetic Center Greenwood, SC

  University of Medicine and Dentistry of New Jersey

  University of Michigan Ann Arbor, MI

  Stratford, NJ

  Richard Robinson Medical Writer

  Tucson, AZ

  Jennifer Ann Roggenbuck, MS, CGC Genetic Counselor

  Hennepin County Medical Center Minneapolis, MN

  Nancy Ross-Flanigan Science Writer

  Belleville, MI

  Stephanie Dionne Sherk Freelance Medical Writer

  Lee Alan Shratter, MD Consulting Radiologist

  Roger E. Stevenson, MD Senior Clinical Geneticist, Senior Clinical Laboratory Geneticist

  Kentfield, CA

  Genevieve T. Slomski, PhD Medical Writer

  New Britain, CT

  Amie Stanley, MS Genetic Counselor

  Medical Genetics The Cleveland Clinic Cleveland, OH

  Constance K. Stein, PhD Director of Cytogenetics, Assistant Director of Molecular

  Diagnostics

  SUNY Upstate Medical University Syracuse, NY

  Contributors

  

A M

Machado-Joseph disease Definition

  Machado-Joseph disease (MJD), also known as spin- ocerebellar ataxia Type 3 (SCA 3), is a rare hereditary disorder affecting the central nervous system, especially the areas responsible for movement coordination of limbs, facial muscles, and eyes. The disease involves the slow and progressive degeneration of brain areas involved in motor coordination, such as the cerebellar, extrapyramidal, py- ramidal, and motor areas. Ultimately, MJD leads to paral- ysis or a crippling condition, although intellectual functions usually remain normal. Other names of MJD are Portuguese-Azorean disease, Joseph disease, Azorean disease.

Causes and symptoms

Description

  Machado-Joseph disease was first described in 1972 among the descendants of Portuguese-Azorean immi- grants to the United States, including the family of William Machado. In spite of differences in symptoms and degrees of neurological degeneration and movement im- pairment among the affected individuals, it was suggested by investigators that in at least four studied families the same gene mutation was present. In early 1976, investi- gators went to the Azores Archipelago to study an existing neurodegenerative disease in the islands of Flores and São Miguel. In a group of 15 families, they found 40 people with neurological disorders with a variety of different symptoms among the affected individuals.

  Another research team in 1976 reported an inherited neurological disorder of the motor system in Portuguese families, which they named Joseph disease. During the same year, the two groups of scientists both published in- dependent evidence suggesting that the same disease was the primary cause for the variety of symptoms observed. When additional reports from other countries and ethnic groups were associated with the same inherited disorder, it was initially thought that Portuguese-Azorean sailors had been the probable disseminators of MJD to other pop- ulations around the world during the sixteenth century pe- riod of Portuguese colonial explorations and commerce. Presently, MJD is found in Brazil, United States, Portugal, Macau, Finland, Canada, Mexico, Israel, Syria, Turkey, Angola, India, United Kingdom, Australia, Japan, and China. Because MJD continues to be diagnosed in a vari- ety of countries and ethnic groups, there are current doubts about its exclusive Portuguese-Azorean origin.

  The gene responsible for MJD appears at chromo- some 14, and the first symptoms usually appear in early adolescence. Dystonia (spasticity or involuntary and repetitive movements) or gait ataxia is usually the initial symptoms in children. Gait ataxia is characterized by un- stable walk and standing, which slowly progresses with the appearance of some of the other symptoms, such as hand dysmetria, involuntary eye movements, loss of hand and superior limbs coordination, and facial dystonia (ab- normal muscle tone). Another characteristic of MJD is clinical anticipation, which means that in most families the onset of the disease occurs progressively earlier from one generation to the next. Among members of the same fam- ily, some patients may show a predominance of muscle tone disorders, others may present loss of coordination, some may have bulging eyes, and yet another sibling may be free of symptoms during his/her entire life. In the late stages of MJD, some people may experience delirium or dementia.

  According to the affected brain area, MJD is classified as Type I, with extrapyramidal insufficiency; Type II, with cerebellar, pyramidal, and extrapyramidal insufficiency; and Type III, with cerebellar insufficiency. Extrapyramidal tracts are networks of uncrossed motor nerve fibers that function as relays between the motor areas and corre- sponding areas of the brain. The pyramidal tract consists of groups of crossed nerves located in the white matter of the spinal cord that conduct motor impulses originated in

Treatment

  Autosomal Relating to any chromosome besides the X and Y sex chromosomes. Human cells con- tain 22 pairs of autosomes and one pair of sex chro- mosomes.

  Cerebellar Involving the part of the brain (cere- bellum) that controls walking, balance, and coor- dination.

Mac hado-J oseph disease Key Terms

Clinical Trials

  Fax: (312) 803-0138. dystonia@dystonia-foundation.org. <http://www.dystonia-foundation.org>.

  ORGANIZATIONS Dystonia Medical Research Foundation. 1 East Wacker Drive, Suite 2430, Chicago, IL 60601-1905. (312) 755-0198;

  Machado-Joseph Disease Fact Sheet. May 5, 2003 (June 7, 2004). <http://www.ninds.nih.gov/ health_and_medical/pubs/machado-joseph.htm>.

  OTHER National Institute of Neurological Disorders and Stroke.

  Fenichel, Gerald M. Clinical Pediatric Neurology: A Signs and Symptoms Approach, 4th ed. Philadelphia: W. B. Saunders Company, 2001.

  The frequency with which such genetic mutations trigger the clinical onset of disease is known as pene- trance. Machado-Joseph disease presents a 94.5% pene- trance, which means that 94.5% of the mutation carriers will develop the symptoms during their lives, and less than 5% will remain free of symptoms. Because the intensity and range of symptoms are highly variable among the af- fected individuals, it is difficult to determine the progno- sis for a given individual. As MJD progresses slowly, most patients survive until middle age or older.

  Further basic research is needed before clinical trials become a possibility for MJD. Ongoing genetic and mo- lecular research on the mechanisms involved in the genetic mutations responsible for the disease will eventually yield enough data to provide for future development and design of experimental gene therapies and drugs specific to treat those with MJD.

  Other symptoms also require palliative treatment, such as muscle cramps, urinary disorders, and sleep problems.

  Dysarthria, or difficulty to speak, and dysphagia, difficulty to swallow, can be treated with proper medication and speech therapy. Physical therapy can help patients with unsteady gait, and walkers and wheelchairs may be needed as the disease progresses.

  Although there is no cure for Machado-Joseph dis- ease, some symptoms can be relieved, The medication Levodopa or L-dopa often succeeds in lessening muscle rigidity and tremors, and is often given in conjunction with the drug Carbidopa. However, as the disease pro- gresses and the number of neurons decreases, this pallia- tive (given for comfort) treatment becomes less effective. Antispasmodic drugs such as baclofen are also prescribed to reduce spasticity.

  Diagnosis depends mainly on the clinical history of the family. Genetic screening for the specific mutation that causes MJD can be useful in cases of persons at risk or when the family history is not known or a person has symptoms that raise suspicion of MJD. Initial diagnosis may be difficult, as people present symptoms easily mis- taken for other neurological disorders such as Parkinson and Huntington diseases, or even multiple sclerosis.

  Trinucleotide A sequence of three nucleotides. the opposite area of the brain to the arms and legs. Pyra- midal tract nerves regulate both voluntary and reflex mus- cle movements. However, as the disease progresses, both motor systems tracks will eventually suffer degeneration.

  Phenotype The physical expression of an individ- ual’s genes. Spasticity Increased mucle tone, or stiffness, which leads to uncontrolled, awkward move- ments.

  Penetrance The degree to which individuals pos- sessing a particular genetic mutation express the trait that this mutation causes. One hundred per- cent penetrance is expected to be observed in truly dominant traits.

  Genotype The genetic makeup of an organism or a set of organisms. Mutation A permanent change in the genetic ma- terial that may alter a trait or characteristic of an in- dividual, or manifest as disease. This change can be transmitted to offspring.

  Extrapyramidal Refers to brain structures located outside the pyramidal tracts of the central nervous system.

  Dysarthria Slurred speech. Dystonia Painful involuntary muscle cramps or spasms.

Prognosis

Resources BOOKS

Diagnosis

Magnetic r esonance imaging (MRI)

  Technician conducting an MRI. (Will & Deni McIntyre/Photo Researchers, Inc. Reproduced by permission.) International Machado-Joseph Disease Foundation, Inc. P.O.

  Box 994268, Redding, CA 96099-4268. (530) 246-4722. MJD@ijdf.net. <http://www.ijdf.net>. National Ataxia Foundation (NAF). 2600 Fernbrook Lane, Suite 119, Minneapolis, MN 55447-4752. (763) 553-

  0020; Fax: (763) 553-0167. naf@ataxia.org. <http://www.ataxia.org>. National Organization for Rare Disorders (NORD). P.O. Box 1968 (55 Kenosia Avenue), Danbury, CT 06813-1968.

  (203) 744-0100 or (800) 999-NORD (6673); Fax: (203) 798-2291. orphan@rarediseases.org. <http://www. rarediseases.org>. Worldwide Education & Awareness for Movement Disorders (WE MOVE). 204 West 84th Street, New York, NY

  10024. (212) 875-8312 or (800) 437-MOV2 (6682); Fax: (212) 875-8389. wemove@wemove.org. <http://www.wemove.org>.

  Sandra Galeotti Macrencephaly see Megalencephaly Mad cow disease see Creutzfeldt-Jakob disease

Magnetic resonance imaging (MRI) Definition

  ❙

  Magnetic resonance imaging (MRI) scanners rely on the principles of atomic nuclear-spin resonance. Using strong magnetic fields and radio waves, MRI collects and correlates deflections caused by atoms into images. MRIs (magnetic resonance imaging tests) offer relatively sharp pictures and allow physicians to see internal bodily struc- tures with great detail. Using MRI technology, physicians are increasingly able to make diagnosis of serious pathol- ogy (e.g., tumors) earlier, and earlier diagnosis often trans- lates to a more favorable outcome for the patient.

  A varying (gradient) magnetic field exists in tissues in the body that can be used to produce an image of the tis- sue. The development of MRI was one of several powerful diagnostic imaging techniques that revolutionized medi- cine by allowing physicians to explore bodily structures and functions with a minimum of invasion to the patient.

  In the last half of the twentieth century, dramatic ad- vances in computer technologies, especially the develop- ment of mathematical algorithms powerful enough to allow difficult equations to be solved quickly, allowed

  MRI to develop into an important diagnostic clinical tool. In particular, the ability of computer programs to eliminate “noise” (unwanted data) from sensitive measurements en- hanced the development of accurate, accessible and rela- tively inexpensive noninvasive technologies.

  Nuclear medicine is based upon the physics of excited atomic nuclei. Nuclear magnetic resonance (NMR) was one such early form of nuclear spectroscopy that eventu- ally found widespread use in clinical laboratory and med- ical imaging. Because a proton in a magnetic field has two quantized spin states, NMR allowed the determination of the complex structure of organic molecules and, ulti- mately, the generation of pictures representing the larger structures of molecules and compounds (such as neural tissue, muscles, organs, bones, etc.). These pictures were obtained as a result of measuring differences between the expected and actual numbers of photons absorbed by a tar- get tissue.

Description

  Groups of nuclei brought into resonance, that is, nu- clei-absorbing and -emitting photons of similar electro- magnetic radiation (e.g., radio waves), make subtle yet distinguishable changes when the resonance is forced to change by altering the energy of impacting photons. The speed and extent of the resonance changes permit a non- destructive (because of the use of low energy photons) de- termination of anatomical structures. This form of NMR

  Magnetic resonance imaging MRI An imaging technique used in evaluation and diagnoses of the brain and other parts of the body.

Megalencephal y

  Resonance A condition in which the applied force (e.g., forced vibrations, forced magnetic field, etc.) becomes the same as the natural fre- quency of the target (e.g., tissue, cell structure, etc.). became the physical and chemical basis of the powerful diagnostic technique of MRI.

Resources PERIODICALS

  A person with megalencephaly has a large, heavy brain. In general, a brain that weighs more than 1600 grams (about 3.5 pounds) is considered megalencephalic. The heaviest brain on record weighed 2850 grams (about 6.3 pounds). Macrocephaly, a related condition, refers to an abnormally large head. Macrocephaly may be due to megalencephaly or other causes such as hydrocephalus (an excess accumulation of fluid in the brain), and brain edema. Megalencephaly may be an isolated finding in an otherwise normal individual or it can occur in association with neurological problems (such as seizures or mental retardation) and/or somatic abnormalities (physical

  Megalencephaly (also called macrencephaly) de- scribes an enlarged brain whose weight exceeds the mean (the average weight for that age and sex) by at least 2.5 standard deviations (a statistical measure of variation). Megalencephaly may also be defined in terms of volume rather than weight. Hemimegalencephaly (or unilateral megalencephaly) is a related condition in which brain en- largement occurs in one hemisphere (half) of the brain.

  Paul Arthur ❙

  AANLIB/home.html>.

  <http://www.cis.rit.edu/htbooks/mri/>. Johnson, K. A., and J. A. Becker. The Whole Brain Atlas. May 9, 2004 (June 2, 2004). <http://www.med.harvard.edu/

  WEBSITES Hornak, J. P. The Basics of MRI. May 9, 2004 (June 2, 2004).

  Young, Emma. “Brain Scans Can Reveal Liars.” New Scientist (November 12, 2001).

  After the September 11, 2001, terrorist attacks, a number of government agencies in the United States began to take a new look at brain scanning technology as a po- tential means of security screening. Such activity, along with an increase of interest in potential brain-wave scan- ning by the Federal Bureau of Investigation (FBI), has raised concerns among civil-liberties groups, which view brain-wave scanning as a particularly objectionable inva- sion of privacy.

  In a 2001 University of Pennsylvania experiment using MRI, 18 subjects were given objects to hide in their pockets, then shown a series of pictures and asked to deny that the object depicted was in their pockets. Included was a picture of the object they had pocketed and so subjects were “lying” (making a deliberate false statement) if they claimed that the object was not in their pocket. An MRI recorded an increase of activity in the anterior cinglate, a portion of the brain associated with inhibition of responses and monitoring of errors, as well as the right superior frontal gyrus, which is involved in the process of paying attention to particular stimuli.

  Studies of the potential of new brain wave scanners explore the possibility that MRI tests could be part of a more accurate form of polygraph (lie detector). Current polygraphs are of debatable accuracy (usually they are not admissible in court as evidence) and measure observable fluctuations in heart rate, breathing, perspiration, etc.

  American chemist and physicist Paul Lauterbur and British physicist Sir Peter Mansfield shared the 2003 Nobel Prize in Physiology or Medicine for their discover- ies concerning the use of magnetic resonance to visualize different structures.

  Healthy and diseased tissues produce different signal patterns and thus allow physicians to identify diseases and disorders.

  The resolution of MRI scanning is so high that they can be used to observe the individual plaques in multiple sclerosis. In a clinical setting, a patient is exposed to short bursts of powerful magnetic fields and radio waves from electromagnets. MRI images do not utilize potentially harmful ionizing radiation generated by three-dimensional x-ray computed tomography (CT) scans, and there are no known harmful side effects. The magnetic and radio wave bursts stimulate signals from hydrogen atoms in the pa- tient’s tissues that, when subjected to computer analysis, create a cross-sectional image of internal structures and organs.